Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of secukinumab for polymyalgia rheumatica
MOH_2025-06-22_014155Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of secukinumab in polymyalgia rheumatica (PMR), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of secukinumab. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
secukinumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on MOH_2025-06-22_014155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-22_014155.